Key Information
- SectorHealthcare
- TypeCo-investment
- StrategyBuyout
- Investment partnerQHP Capital
- Websitehttps://azurity.com/
2021
Year of investment
26
Products in development*
United States
Geography
About
Azurity Pharmaceuticals is a specialty pharma company focused on innovative dosage forms and customised drug formulations that address unmet patient needs. They develop and supply an expanding range of medicines, with a strong emphasis on dose-form innovation. Many of their products cater to small patient groups, treating rare or orphan conditions and addressing the needs of specific populations, all aimed at helping overlooked patients.
Why we invested
Azurity Pharmaceuticals presented an opportunity to invest in a transformative transaction through the combination of Azurity and Arbor pharmaceuticals, creating a differentiated and scaled specialty pharma company at a highly attractive valuation.
Combined business offers dosage innovation and patient centric manufacturing and has substantial scale and synergies from complementary products, pipelines, and capabilities.
Value creation
The value creation plan is focused on increasing market visibility and operating leverage, continuing to build an innovative pipeline of new products to drive continued growth, and strategically in-licensing or acquiring additional innovative products.
Our investment in Azurity Pharmaceuticals was completed alongside QHP Capital, a leading healthcare specialist fund with expertise in the pharma services industry.
*Azurity Pharmaceuticals, as of 2025
The information provided herein is only for professional clients. The case study provided is only for illustrative purpose and is not a recommendation to buy or sell any financial instruments or adopt a specific investment strategy.
Investments with similar characteristics, as well as their past performance may not be repeated in the future. Each asset class have specific risks. Investments in private assets involve a higher degree of risk than more traditional investments. The case study may have been chosen for a variety of reasons, such as being representative of the investment capabilities of the investment team. The circumstances presented are unique to each deal. They do not represent a full picture of the investments made by their respective team and of the product(s) that invested into the asset(s) presented in the case study.